SureNano Science's GEP-44 Targets Obesity Market with Novel Triple Agonist

SureNano Science (CSE: SURE) (OTCQB: SURNF) has announced its featured placement in a BioMedWire editorial that explores next-generation innovation in the rapidly expanding GLP-1 therapeutic market. The editorial highlights the company’s subsidiary GlucaPharm Inc. and its development of GEP-44, a novel triple agonist peptide designed to enhance efficacy, tolerability and delivery flexibility in treating obesity, type 2 diabetes and related metabolic conditions. This development comes at a time when the global GLP-1 market is projected to reach $100 billion by 2030, driven by demand for more effective and patient-friendly treatments.

SureNano Science Ltd. is a Canadian life sciences company focused on acquiring and advancing innovative pharmaceutical and biotechnology assets. Its subsidiary GlucaPharm Inc. is developing GEP44, a patented peptide that targets obesity and metabolic disorders with improved tolerability and potential non-injectable delivery, as noted in a press release dated February 23, 2026. The company also distributes the SureNano(TM) surfactant, a ready-to-mix food grade compound for nanoemulsions, under exclusive licenses in Canada, Oklahoma, and Colorado. SureNano is transitioning into a pharmaceutical-focused entity through the advancement of GEP-44.

The editorial, published by BioMedWire (BMW), a specialized communications platform for the Biotech, BioMed and Life Sciences sectors, is part of a broader effort to highlight promising innovations. BMW is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, which provides distribution through InvestorWire, editorial syndication to 5,000+ outlets, and social media reach. For investors, the latest news on SURNF is available at https://ibn.fm/SURNF.